Journal
CLINICAL THERAPEUTICS
Volume 37, Issue 3, Pages 668-680Publisher
ELSEVIER
DOI: 10.1016/j.clinthera.2014.12.020
Keywords
amyotrophic lateral sclerosis; clinical trials; molecular targets; motor neuron disease; small molecules
Categories
Funding
- MIUR grant [RBFR08RV86]
- Associazione Amici del Centro Dino Ferrari
Ask authors/readers for more resources
Purpose: Amyotrophic latetal sclerosis (ALS) is the most common motor neuron disease in adults. It is almost invariably lethal within a few years after the onset of symptoms. No effective treatment is currently available beyond supportive care and riluzole, a putative glutamate release blocker linked to modestly prolonged survival. This review provides a general overview of preclinical and clinical advances during recent years and summarizes the literature regarding emerging therapeutic approaches, focusing on their molecular targets. Methods: A systematic literature review of PubMed was performed, identifying key clinical trials involving molecular therapies for ALS. In addition, the ALS Therapy Development Institute website was carefully analyzed, and a selection of ALS clinical trials registered at ClinicalTrials.gov has been included. Findings: In the last several years, strategies have been developed to understand both the genetic and molecular mechanisms of ALS. Several therapeutic targets have been actively pursued, including kinases, inflammation inhibitors, silencing of key genes, and modulation or replacement of specific cell populations. The majority of ongoing clinical trials are investigating the safety profiles and tolerability of pharmacologic, gene, and cellular therapies, and have begun to assess their effects On ALS progression. (C) 2015 Elsevier HS Journals, Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available